E Wouters, outside of the submitted work, reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Pfizer and Boehringer Ingelheim, and grants from AstraZeneca, GlaxoSmithKline and Novartis.
H Magnussen received funding from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Takeda and Roche to conduct clinical studies, and has spoken at meetings and is a member of advisory boards for these and other companies.
R Rodriguez-Roisin reports personal fees from AstraZeneca, Boehringer Ingelheim, Mylan, Pearl Therapeutics, Takeda, Teva and Ferrer, and grants and personal fees from Menarini and Almirall.
K Tetzlaff and S Bell are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. PMAC reports financial support in the form of a grant from Boehringer Ingelheim to conduct the study and, outside of the submitted work, reports personal fees from GlaxoSmithKline, AstraZeneca, Takeda and Boehringer Ingelheim, and grants from GlaxoSmithKline and Takeda.